Systematic Investment Plan Report
|
|
|
- Blanche Greene
- 5 years ago
- Views:
Transcription
1 s ICICI Prudential Focused Bluechip Equity Fund - Ret - Growth SBI Bluechip Fund - Growth Nifty 50 S&P BSE Yr Yr Yr Yr Yr Yr Birla Sun Life Frontline Equity Fund - Reg - Growth Birla Sun Life Top 100 Fund - Growth 3 Yr Yr Yr Yr Yr Yr Nifty 50 Franklin India Bluechip - Growth Reliance Top 200 Fund - Growth S&P BSE Sensex 3 Yr Yr Yr Yr Yr Yr DSP BlackRock Top 100 Equity Fund - Reg - Growth Kotak 50 - Reg - Growth S&P BSE Yr Yr Yr Yr Yr Yr Nifty 50
2 Multi Cap Funds L&T India Value Fund - Reg - Growth Birla Sun Life Pure Value Fund - Growth 3 Yr Yr Yr Yr Yr Yr Kotak Select Focus Fund - Reg - Growth Nifty 200 ICICI Prudential Value Discovery Fund - Growth 3 Yr Yr Yr Yr Yr Yr S&P BSE 500 Birla Sun Life Equity Fund - Growth Franklin India High Growth Companies Fund - Growth 3 Yr Yr Yr Yr Yr Yr DSP BlackRock Opportunities Fund - Reg - Growth SBI Magnum Multi Cap Fund - Growth 3 Yr Yr Yr Yr Yr Yr S&P BSE 500 Birla Sun Life Advantage Fund - Growth 3 Yr Yr Yr
3 Funds Reliance Small Cap Fund - Growth HDFC Mid-Cap Opportunities Fund - Growth 3 Yr Yr Yr Yr Yr Yr DSP BlackRock Micro Cap Fund - Reg - Growth # Franklin India Smaller Companies Fund - Growth 3 Yr Yr Yr Yr Yr Yr SBI Small & Midcap Fund - Growth SBI Magnum Midcap Fund - Growth 3 Yr Yr Yr Yr Yr Yr Nifty Mid-Smallcap 400 Sundaram Select Midcap - Reg - Growth Franklin India Prima Fund - Growth S&P BSE MID CAP 3 Yr Yr Yr Yr Yr Yr UTI Mid Cap Fund - Growth Canara Robeco Emerging Equities - Growth 3 Yr Yr Yr Yr Yr Yr
4 s ICICI Prudential Balanced - Growth HDFC Prudence Fund - Growth CRISIL - Aggressive Index CRISIL - Aggressive Index 3 Yr Yr Yr Yr Yr Yr Birla Sun Life Balanced 95 - Growth Reliance RSF - Balanced - Growth 3 Yr Yr Yr Yr Yr Yr Tata - Reg - Growth CRISIL - Aggressive Index CRISIL - Aggressive Index UTI - Growth CRISIL - Aggressive Index CRISIL - Aggressive Index 3 Yr Yr Yr Yr Yr Yr Franklin India - Growth CRISIL - Aggressive Index 3 Yr Yr Yr
5 Index Funds IDFC Nifty Fund - Reg - Growth UTI Nifty Fund - Growth Index Funds Nifty 50 Index Funds Nifty 50 3 Yr Yr Yr Yr Yr Yr ICICI Prudential Nifty Index Fund - Reg - Growth HDFC Index Fund - Nifty Plan Index Funds Nifty 50 Index Funds Nifty 50 3 Yr Yr Yr Yr Yr Yr Franklin India Index Fund - NSE Nifty Plan - Growth Index Funds Nifty 50 3 Yr Yr Yr Disclaimer: - The information contained in this report is obtained from reliable sources In no circumstances should it be considered as an offer to sell/buy or, a solicitation of any offer to, buy or sell the securities or commodities mentioned in this report No representation is made that the transactions undertaken based on the information contained in the report will be profitable, or that they will not result in losses SPA and/or its representatives will not be liable for the recipients investment decision based on this report
Growth of s 1 lac invested on inception date. SIP Performance: Scheme Name 1 Yr 2 Yr 3 Yr 4 Yr 5 Yr. CNX Midcap
BNP Paribas Midcap The investment objective of the is to seek to generate long-term capital appreciation by investing primarily in companies with high growth opportunities in the middle and small capitalization
XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
22nd Century Group, Inc. (XXII - $ Buy)
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.47 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
Fund Performance Bulletin
Fund Performance Bulletin September 22, 2009 September 22, 2009 Page of 0 PATHFINDER B20 Hansard Pathfinder UK 29/0/99.2.. 27..9-8.4 7.82 N/A 2.0 2.9 C20 Hansard Pathfinder America /2/98 0.974.02.8 2.24-2.
Fund Performance Bulletin
Fund Performance Bulletin March 2, 200 March 2, 200 Page of 0 PATHFINDER B20 Hansard Pathfinder UK 29/0/99..444.97.. -2.4.77 27.00.0 2.82 C20 Hansard Pathfinder America /2/98.0. 4. 7.9 7. -20.44-4.89-2.42
Fund Performance Bulletin
Fund Performance Bulletin April 29, 200 April 29, 200 Page of s s s 0 s PATHFINDER B20 Hansard Pathfinder UK 29/0/99..44 -.84 7.40 27. -4.2 9.29.20.0 2.80 C20 Hansard Pathfinder America /2/98.07.2 2.28.7.20-2.9-0.4-2.94
Brisa Concessão Rodoviária. 1Q 2017 Traffic Update
Brisa Concessão Rodoviária 1Q 2017 Traffic Update 15 th May 2017 Disclaimer The information contained herein ( Information ) has been prepared by Brisa Concessão Rodoviária, S.A. ("BCR") and which, according
22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
World leader in navigated, non-invasive brain stimulation therapy and diagnosis
World leader in navigated, non-invasive brain stimulation therapy and diagnosis Martin Jamieson CEO & Chairman of the Board Nexstim Plc Mikko Karvinen CFO Nexstim Plc Corporate Presentation, BioTrinity,
NORTH AMERICAN DERMATOLOGY. M&A Activity and Valuation Trends Q Robert Ullman Managing Director
Robert Ullman Managing Director rullman@dinancapital.com 45.63.44 NORTH AMERICAN DERMATOLOGY M&A Activity and Valuation Trends Q4 205 William Downing Director wdowning@dinancapital.com 602.734.0682 Michael
Investment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information
A Study on Management of Non-Performing Assets (NPAS) In New Generation Private Sector Commercial Banks in India
A Study on Management of Non-Performing Assets (NPAS) In New Generation Private Sector Commercial Banks in India C. Kandasamy 1, Dr. R. Eswaran 2 1 Assistant Professor of Commerce with Computer Application,
Developing Xanamem for Alzheimer s Dementia
Developing Xanamem for Alzheimer s Dementia Dr. Bill Ketelbey CEO, Actinogen Medical Investor Presentation March 2015 Forward Statements This presentation has been prepared by Actinogen Limited. ( Actinogen
PLEO-CMT Top-line Results. Presentation October 16, 2018
PLEO-CMT Top-line Results Presentation October 16, 2018 Disclaimer References herein to this presentation (the Presentation ) shall mean and include this document, any oral presentation accompanying this
Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
Fund Performance Bulletin
Fund Performance Bulletin July 7, 2009 July 7, 2009 Page of 0 PATHFINDER B20 Hansard Pathfinder UK 29/0/99.072.8-2.99 -.42-4.8-20.77 2.8 N/A 7.20 0.72 C20 Hansard Pathfinder America /2/98 0.849 0.97-4.0
M e d i a s e t G r o u p
M e d i a s e t G r o u p 11 th May 2004 2004 First Quarter Results M e d i a s e t G r o u p BROADCASTING MEDIASET 2004 1Q 24 Hours Audience Trend Individuals Share Points Vs 1Q 2003 OTHER SATELLITE 44.0%
GF China Commodities Weekly
GF China Commodities Weekly CHINA ZINC CONCENTRATE SUPPLY WILL BE MORE DEPENDENT ON DOMESTIC MARKETIN 2H16 GFF Commodities Research Contacts : Bonnie Liu;852-3719 1155;bonnieliu@gfgroup.com.hk Zhang Ruoyi;020-85594189;zhangruoyi@gf.com.cn
Analyst Report Written by Mark Bonacci, Chief Financial Analyst
Analyst Report Written by Mark Bonacci, Chief Financial Analyst Mark Bonacci has worked on Wall Street for several years in various financial services roles and is a selfemployed investment analyst and
PRESENTATION. AGM 27 th OCTOBER 2015 ASX: PAA ACN
PRESENTATION AGM 27 th OCTOBER 2015 ASX: PAA ACN 094 006 023 Disclaimer This presentation does not constitute investment advice. Neither this presentation nor the information contained in it constitutes
MDxHealth. Excellent Buy Opportunity. Research Note.
Research Note MDxHealth Excellent Buy Opportunity Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 29 February
2010 First Quarter Results Presentation. 11 th May 2010
2010 First Quarter Results Presentation 11 th May 2010 1 Broadcasting 2 ITALY TV Consumption trend (2003-2010) Average Daily minutes 271 273 270 270 Individuals 269 266 255 250 251 245 251 256 245 244
Latin Manharlal Securities Pvt Ltd. 124 Viraj, S,V.Road, Khar (W), Mumbai S t o c k I d e a
S t o c k I d e a Date: 28-May -12 CMP: `159.50 TARGET: `220.0 Upside: 38% B U Y SENSEX 16218 NIFTY 4920 Eq. Cap. (` Crs) 24.12 Face Value (`) 10.0 M. Cap (` Crs) `385 BSE Code 533200 Latin Manharlal Securities
Liquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)
Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology
Equity Research. Industry Update. Key Takeaways The Impact of The Opioid Epidemic on The Pain Management Landscape
Member FINRA and SIPC Equity Research November 17, 2017 Healthcare Industry Update Key Takeaways The Impact of The Opioid Epidemic on The Pain Management Landscape Conclusions We hosted a key opinion leader
Singapore Exchange Limited 1Q FY2009 Financial Results
Singapore Exchange Limited 1Q FY2009 Financial Results 15 October 2008 Singapore Exchange 1 1Q FY2009 Financial Performance NPAT fell 35% from record 1Q FY2008 Operating profit flat compared to 4Q FY2008
METVIX PDT ON THE MARKET IN GERMANY AND UK
METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone
Transforming IVF and Biological Separations Presentation by Executive Chairman, Alison Coutts
Transforming IVF and Biological Separations Presentation by Executive Chairman, Alison Coutts NuSep (ASX:NSP) key facts No. shares 237,606,002 Market Cap. $7.1 million (@3 cps) No. of shareholders Approx.
MDxHealth. AssureMDx leaves competition behind. Research Note.
Research Note MDxHealth AssureMDx leaves competition behind Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date:
FIRSTQUARTER2018 RESULTSPRESENTATION
FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection
Delivering high quality, cost effective cannabinoid medicines to patients (ASX:AC8) September 2018
Delivering high quality, cost effective cannabinoid medicines to patients (ASX:AC8) September 2018 Disclaimer This presentation has been prepared by AusCann Group Holdings Ltd ACN 008 095 207 ( Company
Sirtex Medical Ltd Buy
Research Sirtex Medical Ltd Buy Price: A$16.32 Price Target: A$20.50 ASX: SRX 21 April 2017 Sirtex Medical (SRX) is a global medical device company which targets cancer therapies, with its lead product
MDxHealth. Acceleration of payor coverage ConfirmMDx. Research Note.
Research Note MDxHealth Acceleration of payor coverage ConfirmMDx Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com
MDxHealth. Strong outlook for Research Note.
Research Note MDxHealth Strong outlook for 2017 Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 23 February
SAGE-547 s mechanism of action is already addressed by other drugs that are commonly used to treat SRSE patients
April 2016 Sage Therapeutics, Inc. (SAGE) Sell-Side Assumptions Are Wrong: Core Placebo Response Rate Assumption is Way Off and SAGE-547 Still Confers No Meaningful Benefit to SRSE Patients Following our
Thyrocare Wellness for your Wealth
A quality report by JainMatrix Investments Thyrocare Wellness for your Wealth Date 26 th April 2016 Price range: Rs. 420-446 and Period: 27-29 th April 2016 Advice: BUY with a 2 year perspective Mid Cap
ACACIA PHARMA ANNOUNCES ITS INTENTION TO LAUNCH AN INITIAL GLOBAL OFFERING AND TO LIST ITS SHARES ON EURONEXT BRUSSELS
This announcement is an advertisement for the purposes of the Prospectus Rules of the Financial Conduct Authority ( FCA ) and not a prospectus and not an offer of securities for sale in any jurisdiction,
Keltner Channels & Moving Average Envelopes July 19, 2016
Keltner Channels & Moving Average Envelopes July 19, 2016 Disclaimer U.S. Government Required Disclaimer Commodity Futures Trading Commission Futures and Options trading has large potential rewards, but
SUMMARY TERM SHEET. Sl. Particulars Details 1. Issuer L&T Finance Holdings Limited (the Company / the Issuer / L&TFHL )
SUMMARY TERM SHEET Sl. Particulars Details 1. Issuer L&T Finance Holdings Limited (the Company / the Issuer / L&TFHL ) 2. Date of resolution May 28, 2014 passed by the Board of Directors authorizing the
Dabur India Limited. October 10, CMP (Rs.) 284. Key Developments
Oct-15 Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 s. Dabur India Limited. October 10, 2016 BSE Code: 500096 NSE Code: DABUR Reuters Code: DABU.NS Bloomberg Code:
Small-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK
Small-Cap Research February 2, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive
1Q 2009 Results Presentation. 12 May 2009
1Q 2009 Results Presentation 12 May 2009 1 Broadcasting 2 MEDIASET 2009 1Q Total Audience TOTAL AUDIENCE (Jan-Mar) * Individuals Δ vs. 2008 +5.3% 15-64 years +5.6% 1Q TV CONSUMPTION (2000-2009) Average
Development of Women Entrepreneurship Through SHG-A Case Study. Indira Nair, Associate Professor, Smt. C.H.M. College, Ulhasnagar.
Development of Women Entrepreneurship Through SHG-A Case Study. Indira Nair, Associate Professor, Smt. C.H.M. College, Ulhasnagar. Key Words: SHG, women entrepreneur, leader, marketing. Introduction: India
Mortgage Rate Sheet Intermediary Rate Sheet Rates Effective From 15th December 2017
Mortgage Sheet Intermediary Sheet s Effective From 15th December 2017 Contents s... Purchase, 4 & 5...2,3 Family Spingboard & Help to Buy Purchase s...5...2,3, 4 & 5 s...6,7 Family Spingboard, Scotland
LAIDLAW & COMPANY Est. 1842
LAIDLAW & COMPANY London New York San Francisco Stamford Ft. Lauderdale EQUITY RESEARCH Company Report Mast Therapeutics (MSTX - $ 0.50) Vepoloxamer Pre-clinical Data to Be Presented at Sickle Cell Disease
Sector Update. Rubber Glove. Robust Demand Spills Over to 2010
PP10551/10/2010(025682) 13 January 2010 Jason Yap +60 (3) 9207 7698 Jason.yap@osk.com.my Sector Update Rubber Glove MALAYSIA EQUITY Investment Research Daily News Robust Demand Spills Over to 2010 OVERWEIGHT
Small-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK
Small-Cap Research November 16, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final
Compensation and Reimbursement of Expenses to Ladenburg Thalmann and Representatives
Compensation and Reimbursement of Expenses to Ladenburg Thalmann and Representatives Ladenburg Thalmann Financial Services Inc. and its affiliates, which include Ladenburg Thalmann & Co. Inc., Securities
Compensation and Reimbursement of Expenses to Ladenburg Thalmann and Representatives
Compensation and Reimbursement of Expenses to Ladenburg Thalmann and Representatives Ladenburg Thalmann Financial Services Inc. and its affiliates, which include Ladenburg Thalmann & Co. Inc., Securities
For personal use only
Developing Xanamem for Alzheimer s Dementia Dr. Bill Ketelbey CEO, Actinogen Medical Investor Presentation April 2015 Forward Statements 2For personal use only This presentation has been prepared by Actinogen
DISCLOSEABLE AND CONNECTED TRANSACTION AND PROPOSED APPOINTMENT OF CHIEF EXECUTIVE OFFICER
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness
Corcept Therapeutics, Inc.
March 20, 2015 Corcept Therapeutics, Inc. NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/20/2015 Current Price (03/19/15) $5.85 Target Price $6.25 (CORT-NASDAQ) SUMMARY
Tamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
Compensation and Reimbursement of Expenses to Ladenburg Thalmann and Representatives
Compensation and Reimbursement of Expenses to Ladenburg Thalmann and Representatives Ladenburg Thalmann Financial Services Inc. and its affiliates, which include Ladenburg Thalmann & Co. Inc., Securities
SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
Tonix Pharmaceuticals
Tonix Pharmaceuticals PTSD awareness day and earnings update Financial and development update Pharma & biotech Tonix recently held a post-traumatic stress disorder (PTSD) awareness day to highlight the
Gavi Risk Appetite Statement Version 2.0
Gavi Risk Appetite Statement Version 2.0 DOCUMENT ADMINISTRATION VERSION NUMBER 1.0 2.0 APPROVAL PROCESS Reviewed and recommended by: Gavi Programme & Policy Committee Reviewed and approved by: Gavi, the
Q4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Q4 Report 2018 Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation has been prepared by Calliditas Therapeutics AB
COMMERCIAL SOLUTIONS
COMMERCIAL SOLUTIONS YOUR GUIDE TO MAXIMIZE REVENUE As the only true commercial infrared sauna provider, we understand the importance of maximizing revenue with your sauna equipment. Based on years of
Ace Healthways Committed Excellence in Diagnostics. Profile of Ace Healthways
Profile of Ace Healthways About Ace Ace Healthways, a unique State of Art Independent Diagnostic Centre providing round the clock quality services in Pathology, Radiology and Nuclear Medicine all under
For personal use only
Virtus Health (ASX. VRT) Sue Channon CEO and Glenn Powers CFO Navigating Future Growth, UBS Australasian Conference 7 November, 2016 DISCLAIMER 2 The material in this presentation has been prepared by
PRESENTATION ON 2017 THIRD QUARTERLY RESULTS
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness
Zacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
Acquisition of Dimerix Bioscience A Clinical Stage Biotechnology Company
Acquisition of Dimerix Bioscience A Clinical Stage Biotechnology Company Dr. Anton Uvarov Executive Director Investor Presentation 13 May 2015 1 Important information This presentation has been prepared
PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes
PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes Sébastien Bolze 1 ; Sophie Hallakou-Bozec 1 ; Michael Roden 2, 3,4 ; Julien Roux
Acquisition of BP s Interests in Bruce, Keith and Rhum Fields in the North Sea Frequently Asked Questions
Acquisition of BP s Interests in Bruce, Keith and Rhum Fields in the North Sea Frequently Asked Questions 1. What is Serica buying? Serica Energy is buying the Bruce, Keith and Rhum (BKR) package of assets
Advancing Mitochondrial Medicine. Thomas Meier, PhD CEO
Advancing Mitochondrial Medicine Thomas Meier, PhD CEO Disclaimer 2 This presentation is not and under no circumstances to be construed as a solicitation, offer, or recommendation, to buy or sell securities
Equity markets. Major advances in cancer therapeutics - update 6 26 April Investment Guidance
Equity markets Major advances in cancer therapeutics - update 6 26 April 2016 CIO WM Research Jerome Brimeyer, Equity Sector Strategist, jerome.brimeyer@ubs.com This investment theme recommends companies
Korean Airlines Q Results
Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and
Non Performing Assets (NPAs): A Comparative Analysis of SBI and ICICI Bank
Non Performing Assets (NPAs): A Comparative Analysis of SBI and ICICI Bank RAJESHWARI PARMAR Assistant Professor (Finance), Parul Institute of Business Administration, Limda. District: Vadodara Gujarat
For personal use only ASX: PAA ACN
ACN 094 006 023 Investor Presentation January 2016 1 Disclaimer DISCLAIMER This presentation has been prepared by PharmAust Limited () (ACN: 094 006 023) (the Co pa. It does not purport to contain all
commercial real estate
August 15 Asset Management Documeent title on one or two Defensive lines in Gustan investing Book in pt U.S. commercial real estate TIAA-CREF Global Real Estate Strategy & Research Martha Peyn, Ph.D. Managing
Chaired by: Clare Bailhé Apollo MidCap Brendan Dillon UBS Lee Grinberg Elliott Management Christina Minnis Goldman Sachs George Mueller KKR
Chaired by: Clare Bailhé Apollo MidCap Brendan Dillon UBS Lee Grinberg Elliott Management Christina Minnis Goldman Sachs George Mueller KKR AJ Murphy Silver Lake Geoff Oltmans Silver Lake Jeff Rowbottom
Cannabis Regulation in Canada:
Cannabis Regulation in Canada: Where We Came From, Where We Are and What s Coming Next Jonathan Sherman Cassels Brock & Blackwell LLP Sherri Altshuler Aird & Berlis LLP Canada, In Brief Right Now... Legal
ADVERTISING POLICY. 1. Definitions. i. an Advertisement, ii. any publication or communication in any medium to any patient, prospective
ADVERTISING POLICY This Advertising Policy has been established by the Board of the College of Naturopathic Physicians of British Columbia under the College Bylaws and the Health Professions Act. 1. Definitions
Presentation to 2019 JP Morgan Healthcare Conference
For immediate release 10 January 2019 Presentation to 2019 JP Morgan Healthcare Conference Please find attached CSL Limited s presentation at the 2019 JP Morgan Healthcare Conference. For further information,
Advancing New Treatments for DMD and C. difficile Infection
Advancing New Treatments for DMD and C. difficile Infection Oppenheimer 25 th Annual Healthcare Conference December 2014 Legal Disclaimer No undertaking, representation, warranty or other assurance is
IPR and the CUSTOMS ENFORCEMENT NETWORK (CEN) THE STARTING POINT
IPR and the CUSTOMS ENFORCEMENT NETWORK (CEN) Larry L. Burton Technical Officer World Customs Organization THE STARTING POINT Customs Recognizes the Scope of the Problem (Virtually no Category of Goods
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
Sharing of EP 200 Inspection Findings
1 Sharing of EP 200 Inspection Findings PRACTITIONERS CONFERENCE 2018 1 June 2018 Ms Ng Meow Ling Chief Inspector Practice Monitoring Department, ACRA 2 Disclaimer These slides are not to be cited, copied
Novo Nordisk has proposed to acquire Ablynx for up to per share in cash, consisting of upfront and 2.50 in Contingent Value Rights
Novo Nordisk has proposed to acquire Ablynx for up to 30.50 per share in cash, consisting of 28.00 upfront and 2.50 in Contingent Value Rights Proposal consists of upfront cash consideration of 28.00 per
Small-Cap Research. Celator Pharma (CPXX-NASDAQ)
Small-Cap Research June 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: Positive top line data reported for
Small-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK
Small-Cap Research September 12, 2014 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set
ASX Small to Mid Caps New York Conference. March 1, 2012
ASX Small to Mid Caps New York Conference March 1, 2012 Important Notice Not an Offer for Securities This presentation has been prepared by REVA Medical, Inc. (REVA or the Company) solely for its use at
Investor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
Prima Biomed Ltd ASX CODE: PRR. Buy. Australian Biotech with Phase II/III Cancer Vaccine - Investment Summary. Action and Recommendation
29 January 2013 ASX CODE: PRR Buy Prima Biomed Ltd Australian Biotech with Phase II/III Cancer Vaccine - Investment Summary Capital Structure Sector Healthcare Share Price (A$) A$0.105 Target Price A$0.27
Overview of CARE Programs in Malawi
Overview of CARE Programs in Malawi CARE Malawi January 2011 2002, CARE USA. All rights reserved. CARE Malawi CARE established operations in Malawi in 1998. Programs include food security, agriculture,
An exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
For personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
For personal use only. A new company with: a new technology platform for cancer drug development a new management team a new Board
A new company with: a new technology platform for cancer drug development a new management team a new Board Disclaimer This presentation is confidential and is not an offer or a recommendation or intended
January 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
Nitrazepam. Nitrazepam Tablets TAJ GROUP PHARMACEUTICAL B U S I N E S S. Generics. Active Ingredients: Each tablet contains 10 mg Nitrazepam
Nitrazepam, Nitrazepam India, Nitrazepam manufacturers India, side effects Nitrazepam manufacturers, Taj Pharma India, Nitrazepam overdose, Nitrazepam drug, Nitrazepam composition, Manufacturing Pharmaceutical,
The Role of Microfinance for Empowerment of Poor Women in Yemen
The Role of Microfinance for Empowerment of Poor Women in Yemen Ali Saleh Alshebami School of Commerce & Management Science, SRTM University, India E-mail: Talk2aliii@gmail.com Prof. D. M. Khandare School
TRI ORIGIN MINERALS LTD
TRI ORIGIN MINERALS LTD Mines And Wines Conference September 2007 Woodlawn Zinc-Copper Projects ASX Code: TRO DISCLAIMER The Information contained in this presentation has been prepared using the information
High Oleic Soybean Oil Panel. National Institute of Oilseed Products March 17, 2015
High Oleic Soybean Oil Panel National Institute of Oilseed Products March 17, 2015 John Becherer, United Soybean Board USB farmer commitment and experience Acreage expansion Security of supply John Becherer,
About Dr.Santosh Kumar
KNEE REPLACEMENT About Dr.Santosh Kumar MBBS (JIPMER), D.ORTH (JIPMER); MCh ORTH (SCYCHELLS) Head : Department of Computer Assisted Joint Replacement Surgery : BELLE VUE CLINIC JOINT REPLACEMENT SURGEON,
Transplant Tourism: Ethical Issues
Transplant Tourism: Ethical Issues Linda Wright Director of Bioethics University Health Network, Toronto Joint Centre for Bioethics & Dept. of Surgery, University of Toronto onto B.C. Kidney Days. 19th
MARCH 2014 RESULTS PRESENTATION Madrid, 2014
MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted